Literature DB >> 8099333

P-glycoprotein-mediated transcellular transport of MDR-reversing agents.

T Saeki1, K Ueda, Y Tanigawara, R Hori, T Komano.   

Abstract

Understanding of the interactions between P-glycoprotein and multidrug resistance (MDR) reversing agents is important in designing more effective MDR modulators. We examined transcellular transport of several MDR modulators by using a drug-sensitive epithelial cell line, LLC-PK1, and its transformant cell line, LLC-GA5-COL300, which expresses human P-glycoprotein on the apical surface. Basal-to-apical transports of azidopine and diltiazem across the LLC-GA5-COL300 monolayer were increased and apical-to-basal transports were decreased compared to those across the LLC-PK1 monolayer, indicating that P-glycoprotein transports azidopine and diltiazem. Movements of nitrendipine and staurosporine across the epithelial monolayer were not affected by P-glycoprotein. These results suggests that some MDR modulators exert their inhibitory effect not only by blocking the initial binding of anticancer drugs but throughout the course of the transport process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099333     DOI: 10.1016/0014-5793(93)81540-g

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  Bioavailability enhancers of herbal origin: an overview.

Authors:  Kritika Kesarwani; Rajiv Gupta; Alok Mukerjee
Journal:  Asian Pac J Trop Biomed       Date:  2013-04

2.  Exposure-response relationships and drug interactions of sirolimus.

Authors:  James J Zimmerman
Journal:  AAPS J       Date:  2004-10-15       Impact factor: 4.009

3.  Experimental and computational studies of epithelial transport of mefenamic acid ester prodrugs.

Authors:  Kamonthip Wiwattanawongsa; Vimon Tantishaiyakul; Luelak Lomlim; Yon Rojanasakul; Sirirat Pinsuwan; Sanae Keawnopparat
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

4.  Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.

Authors:  M Katoh; M Nakajima; H Yamazaki; T Yokoi
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

5.  Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells.

Authors:  Katrina L Mealey; Rola Barhoumi; Robert C Burghardt; Stephen Safe; Deborah T Kochevar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects.

Authors:  Kyoung-Ah Kim; Pil-Whan Park; Ji-Young Park
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

7.  Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.

Authors:  Tomoko Konishi; Hideo Satsu; Yasuo Hatsugai; Koichi Aizawa; Takahiro Inakuma; Shinji Nagata; Sho-Hei Sakuda; Hiromichi Nagasawa; Makoto Shimizu
Journal:  Br J Pharmacol       Date:  2004-09-06       Impact factor: 8.739

Review 8.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.

Authors:  R García del Moral; F O'Valle; M Andújar; M Aguilar; M A Lucena; J López-Hidalgo; C Ramírez; M T Medina-Cano; D Aguilar; M Gómez-Morales
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 10.  The MDR1 (ABCB1) gene polymorphism and its clinical implications.

Authors:  Ichiro Ieiri; Hiroshi Takane; Kenji Otsubo
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.